In:
Oncology, S. Karger AG, Vol. 68, No. 4-6 ( 2005), p. 333-340
Abstract:
〈 i 〉 Objectives: 〈 /i 〉 The purpose of this study was to evaluate the antitumor activity and safety of an epirubicin, cisplatin, and capecitabine (ECX) combination in patients with metastatic or advanced gastric cancer. 〈 i 〉 Patients and Methods: 〈 /i 〉 Patients with metastatic or advanced measurable gastric adenocarcinoma received ECX combination chemotherapy. Epirubicin 50 mg/m 〈 sup 〉 2 〈 /sup 〉 and cisplatin 60 mg/m 〈 sup 〉 2 〈 /sup 〉 were administered on day 1 by intravenous injection. Capecitabine 1,000 mg/m 〈 sup 〉 2 〈 /sup 〉 twice daily was administered orally on day 1–14. The cycle was repeated every 3 weeks. 〈 i 〉 Results: 〈 /i 〉 Fifty-four patients were enrolled in this study. Fifty patients were assessable for responses and 53 for toxicity. A total of 250 cycles were administered. The overall best response rate by intent-to-treat analysis was 59% including 52% partial responses and 7% complete responses. Median response duration and time to progression was 5.8 and 6 months, respectively. Median survival for all patients was 9.6 months (95% CI, 8.7–10.5 months). The most common grade 3/4 hematological adverse event was neutropenia in 31% (76 cycles) including febrile neutropenia in 4.8% (11 cycles). Non-hematological toxicity was generally mild and reversible. Grade 3/4 nausea, vomiting and stomatitis occurred in 8, 9, and 8% of the patients, respectively. Hand-foot skin reactions developed in 51% of patients, but most were self-limited. Grade 3 occurred in only 4%. One patient died of neutropenic sepsis. 〈 i 〉 Conclusions: 〈 /i 〉 ECX combination regimen showed high anti-tumor activity with a tolerable toxicity pattern as a front-line chemotherapy for patients with metastatic or advanced gastric cancer.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2005
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Bookmarklink